An Open-label Phase 2 Study of Eneboparatide, a Novel PTH Receptor 1 Agonist, in Hypoparathyroidism.
Takacs I, Mezosi E, Soto A, Kamenický P, Figueres L, Galvez Moreno MA, Lemoine S, Borson-Chazot F, Capel I, Ouldrouis T, Lucas N, Allas S, Sumeray M, Ovize M, Mannstadt M.
Takacs I, et al. Among authors: sumeray m.
J Clin Endocrinol Metab. 2024 Aug 13;109(9):2199-2209. doi: 10.1210/clinem/dgae121.
J Clin Endocrinol Metab. 2024.
PMID: 38449442
Clinical Trial.